SCHEMBL3568069

SCHEMBL3568069

O=C(O)c1ccc(OCCOc2ccccc2NC(=O)c2cc(F)cc(F)c2)cc1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CACNA1H O95180 4/20 0.53
PKM P14618 1/20 0.52
CACNA1B Q00975 2/20 0.52
SMN1; SMN2 Q16637 4/20 0.49
LMNA P02545 1/20 0.49
RAB9A P51151 4/20 0.48
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
NPC1 O15118 3/20 0.48
CASP3 P42574 1/20 0.48
TAAR1 Q96RJ0 1/20 0.48
SENP7 Q9BQF6 1/20 0.48
GAA P10253 1/20 0.48
HDAC1 Q13547 1/20 0.47
HDAC2 Q92769 1/20 0.47
PLK1 P53350 1/20 0.47
HTT P42858 1/20 0.46
PTPN1 P18031 1/20 0.46
P4HTM Q9NXG6 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3552439 0.91 CACNA1H (0.52) CACNA1HPKMCACNA1BSMN1; SMN2LMNA
SCHEMBL3559976 0.88 PKM (0.60) CACNA1HPKMCACNA1BSMN1; SMN2LMNA
SCHEMBL27716694 0.85 SMN1; SMN2 (0.58) CACNA1HCACNA1BSMN1; SMN2LMNAMEN1
SCHEMBL3563105 0.84 L3MBTL1 (0.60) CACNA1HPKMCACNA1BSMN1; SMN2LMNA
SCHEMBL3555876 0.83 CACNA1H (0.57) CACNA1HPKMCACNA1BSMN1; SMN2LMNA
SCHEMBL3565241 0.83 KMT2A (0.57) CACNA1HPKMCACNA1BSMN1; SMN2LMNA
SCHEMBL3557989 0.83 F10 (0.62) CACNA1HPKMCACNA1BSMN1; SMN2LMNA
SCHEMBL3558076 0.82 SMN1; SMN2 (0.56) CACNA1HPKMCACNA1BSMN1; SMN2LMNA
SCHEMBL3556306 0.81 RAB9A (0.56) CACNA1HPKMCACNA1BSMN1; SMN2LMNA
SCHEMBL3554988 0.81 GAA (0.57) CACNA1HPKMCACNA1BSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7816397-B2 Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2010-10-19 US claimed
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes MERCK PATENT GMBH (DE) 2008-02-21 US claimed
US-7816397-B2 Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2010-10-19 US disclosed
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes MERCK PATENT GMBH (DE) 2008-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes SLC5A1, ALDH7A1, ASS1 CACNA1H 2058/4885PKM 990/4885CACNA1B 1921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.